UPDATE – Galectin Therapeutics to Present Six Scienti

New data regarding the mechanism of action of belapectin to inhibit galectin-3Unique pharmacokinetic profile of belapectin in patients with hepatic...

Related Keywords

Naga Chalasani , Eric Lawitz , Andrea Mladenovic , Archita Parikh Desai , Stephena Harrison , D Harold Shlevin , Raj Vuppalanchi , Pol Boudes , Barbara Lomeli , Harold Shlevin , Nagap Chalasani , Zachary Goodman , Eliezer Zomer , Khim Chng , Juan Rondon , Mazen Noureddin , International Study Evaluating The Efficacy , Nuclear Magnetic Resonance , Galectin Therapeutics Inc , Nasdaq , Liver Cirrhosis , Artificial Intelligence , Liver Meeting , American Association , Liver Diseases , Chief Medical Officer , Non Alcoholic Fatty Liver Disease , Galectin Therapeutic , Portal Hypertension , Natural History , Dean Tai , Elaine Lay Khim Chng , Seamless Adaptive Phase , Placebo Controlled Multicenter , International Study Evaluating , Esophageal Varices , Nasdaq Galt , Ash Cx , R Md 02 , Keytruda , Ash Cirrhosis , Nio Ceo , Io Ceo And Investor Contacts ,